AI in biopharma

Digital

Many biotechs remain locked out of the AI revolution by a combination of cost, complexity, and lack of access to state-of-the-art infrastructure.

Digital

In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.

R&D

A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.

Digital

Read Zühlke’s new white paper, ‘Future Proof Production: Implementing AI in pharmaceutical manufacturing’ today.

R&D

Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.

Digital

At BIO 2025 in Boston today, pharma and biotech leaders discussed the current state of AI in the drug development life cycle.